Decision Resources studied findings from the Pharmacor topic “Breast Cancer” that showed the possible financial effects of new therapies. Their findings projected a reduction in sales from generic and biosimilar erosion of some key agents in the next decade. However, they said this reduction will be offset by an annual increase in breast cancer incidence and the introduction of high-priced emerging therapies, according to the release.
Related Articles on Hospital Oncology:
CDC Releases Guide on Infection Prevention in Outpatient Oncology Settings
Brigham and Women’s, Dana-Farber Launch Research Project for Cancer Genomics
South Carolina’s St. Francis Health System Opens $3M Breast Health Center
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
